PURPOSE: To determine the incidence and prognostic significance of eradication of cytologically proven axillary lymph node metastases in breast cancer patients treated with primary chemotherapy. PATIENTS AND METHODS: Between January 1985 and December 1994, 152 breast cancer patients with invasive T1 to T3 tumors and axillary metastases cytologically proven by fine-needle sampling underwent primary chemotherapy followed by lumpectomy or mastectomy, level I and II axillary lymph node dissection, and irradiation. We studied pathologic complete responses (pCRs) of axillary nodes and breast tumors, as well as predictors of distant metastases. RESULTS: Thirty-five patients (23%) had axillary pCRs, and 20 patients (13.2%) had pCRs of primary breast tumors. Scarff-Bloom-Richardson grade 3 tumors (P =.04) and a clinical response to chemotherapy > or = 50% (P =.003) were associated with negative axillary status at dissection. An initial tumor size < or = 3 cm (63 patients) was associated with pCR of the primary tumor (P =.02) but not with complete histologic clearance of axillary lymph nodes. The median length of follow-up was 75 months. In the univariate analysis, age greater than 40 years (P =.003), absence of residual nodal disease (P =.01), and pCR of the tumor (P =.05) were associated with better distant disease-free survival. Five-year distant disease-free survival rates were 73.5% +/- 14.9% among patients with no involved nodes at the time of surgery and 48.7% +/- 9.2% among patients with residual nodal disease. In the multivariate Cox regression analysis, parameters associated with poor distant disease-free survival were age < or = 40 years (P =.002), persistence of nodal involvement (P =.03), and S-phase fraction greater than 4% (P =.02). CONCLUSION: Our results suggest that axillary status is a better prognostic factor than response of the primary tumor to primary chemotherapy.
PURPOSE: To determine the incidence and prognostic significance of eradication of cytologically proven axillary lymph node metastases in breast cancerpatients treated with primary chemotherapy. PATIENTS AND METHODS: Between January 1985 and December 1994, 152 breast cancerpatients with invasive T1 to T3 tumors and axillary metastases cytologically proven by fine-needle sampling underwent primary chemotherapy followed by lumpectomy or mastectomy, level I and II axillary lymph node dissection, and irradiation. We studied pathologic complete responses (pCRs) of axillary nodes and breast tumors, as well as predictors of distant metastases. RESULTS: Thirty-five patients (23%) had axillary pCRs, and 20 patients (13.2%) had pCRs of primary breast tumors. Scarff-Bloom-Richardson grade 3 tumors (P =.04) and a clinical response to chemotherapy > or = 50% (P =.003) were associated with negative axillary status at dissection. An initial tumor size < or = 3 cm (63 patients) was associated with pCR of the primary tumor (P =.02) but not with complete histologic clearance of axillary lymph nodes. The median length of follow-up was 75 months. In the univariate analysis, age greater than 40 years (P =.003), absence of residual nodal disease (P =.01), and pCR of the tumor (P =.05) were associated with better distant disease-free survival. Five-year distant disease-free survival rates were 73.5% +/- 14.9% among patients with no involved nodes at the time of surgery and 48.7% +/- 9.2% among patients with residual nodal disease. In the multivariate Cox regression analysis, parameters associated with poor distant disease-free survival were age < or = 40 years (P =.002), persistence of nodal involvement (P =.03), and S-phase fraction greater than 4% (P =.02). CONCLUSION: Our results suggest that axillary status is a better prognostic factor than response of the primary tumor to primary chemotherapy.
Authors: Ana María García Vicente; Ángel Soriano Castrejón; Alberto León Martín; Fernanda Relea Calatayud; María Del Mar Muñoz Sánchez; Miguel Ángel Cruz Mora; Germán Andrés Jiménez Londoño; Ruth Espinosa Aunión Journal: Eur J Nucl Med Mol Imaging Date: 2014-04-18 Impact factor: 9.236
Authors: Sarah S Mougalian; Mike Hernandez; Xiudong Lei; Siobhan Lynch; Henry M Kuerer; William F Symmans; Richard L Theriault; Bruno D Fornage; Limin Hsu; Thomas A Buchholz; Aysegul A Sahin; Kelly K Hunt; Wei Tse Yang; Gabriel N Hortobagyi; Vicente Valero Journal: JAMA Oncol Date: 2016-04 Impact factor: 31.777
Authors: Marieke E Straver; Tjeerd S Aukema; Renato A Valdes Olmos; Emiel J T Rutgers; Kenneth G A Gilhuijs; Margaret E Schot; Wouter V Vogel; Marie-Jeanne T F D Vrancken Peeters Journal: Eur J Nucl Med Mol Imaging Date: 2010-02-04 Impact factor: 9.236
Authors: R E Coleman; M C Winter; D Cameron; R Bell; D Dodwell; M M Keane; M Gil; D Ritchie; J L Passos-Coelho; D Wheatley; R Burkinshaw; S J Marshall; H Thorpe Journal: Br J Cancer Date: 2010-03-16 Impact factor: 7.640
Authors: Yesim Eralp; Terry L Smith; Kadri Altundağ; Shu-Wan Kau; Jennifer Litton; Vicente Valero; Aman Buzdar; Gabriel N Hortobagyi; Banu Arun Journal: J Cancer Res Clin Oncol Date: 2008-06-26 Impact factor: 4.553